STUB1 and myocarditis: In a multivariate competing risk analysis, CHIP status doubled the risk of developing ICI myocarditis, similar to the risk of dual ICI use (CHIP status HR 2.74, 95% CI: 1.44–5.22, p = 0.002 vs dual ICI use HR 2.39, 95% CI: 1.11–5.14, p = 0.026).